Takada M, Fukuoka M, Negoro S, Masuda N, Kudo S
Osaka Prefectural Habikino Hospital.
Gan To Kagaku Ryoho. 1990 Oct;17(10):2005-12.
Dose intensity (DI) is defined as the amount of drugs administered per unit time (mg/m2/wk). Recently this concept is thought to be one of the most important tactics to improve the chemotherapeutic results. In this article, we summarized the reports about the impact of dose intensity chemotherapy on various malignancies and the experimental results in animal models. As the application of this concept for the treatment of lung cancer, we conducted the following trials. For the patients with small-cell lung cancer (SCLC), weekly intensive chemotherapy employing cisplatin, oncovin, doxorubicin, and etoposide (CODE regimen) was performed. Fifteen (88%) of 17 patients responded to this regimen, including 5 (29%) complete responders. The median survival time for all patients was 45 weeks. For the patients with non-small cell lung cancer (NSCLC), short interval (3 weeks) MVP (mitomycin, vindesine, and cisplatin) therapy using with recombinant human granulocyte-colony stimulating factor (rhG-CSF) was performed. This study was aimed at improving the therapeutic result by reducing the cycle length of MVP regimen through the use of rG-CSF. Thirty-two out of 40 patients could receive two or more cycles of MVP regimen on schedule. These results in SCLC and NSCLC suggest that does intensity chemotherapy can improve the outcome for patients with these disease.
剂量强度（DI）定义为单位时间内给予的药物量（mg/m²/周）。最近，这一概念被认为是提高化疗效果的最重要策略之一。在本文中，我们总结了关于剂量强度化疗对各种恶性肿瘤影响的报告以及动物模型的实验结果。作为这一概念在肺癌治疗中的应用，我们进行了以下试验。对于小细胞肺癌（SCLC）患者，采用顺铂、长春新碱、阿霉素和依托泊苷进行每周一次的强化化疗（CODE方案）。17例患者中有15例（88%）对该方案有反应，其中5例（29%）完全缓解。所有患者的中位生存时间为45周。对于非小细胞肺癌（NSCLC）患者，使用重组人粒细胞集落刺激因子（rhG-CSF）进行短间隔（3周）的MVP（丝裂霉素、长春地辛和顺铂）治疗。本研究旨在通过使用rG-CSF缩短MVP方案的周期长度来提高治疗效果。40例患者中有32例能够按计划接受两个或更多周期的MVP方案。SCLC和NSCLC的这些结果表明，剂量强度化疗可以改善这些疾病患者的预后。
